NDSIB
NBIX icon

North Dakota State Investment Board’s Neurocrine Biosciences NBIX Stock Holding History

North Dakota State Investment Board’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$485K Buy
2,880
+49
+2% +$7.27K 0.02% 505
2026
Q1 		$373K Sell
2,831
-578
-17% -$76.7K 0.02% 551
2025
Q4 		$483K Buy
+3,409
New +$494K 0.02% 532

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

North Dakota State Investment Board's NBIX Position: Q2 2026 in Review

North Dakota State Investment Board increased its Neurocrine Biosciences (NBIX) stake by 1.7% in Q2 2026, buying an estimated $7.27K and bringing the position to 2,880 shares worth $485K. The position accounts for 0.02% of the portfolio, ranked #505.

North Dakota State Investment Board first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • North Dakota State Investment Board held 2,880 shares of Neurocrine Biosciences worth $485K as of Q2 2026.
  • North Dakota State Investment Board bought 49 Neurocrine Biosciences shares in Q2 2026, an estimated $7.27K.
  • Neurocrine Biosciences made up 0.02% of North Dakota State Investment Board's portfolio in Q2 2026, its #505 holding.
  • North Dakota State Investment Board first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on North Dakota State Investment Board's 13F filing for Q2 2026, filed 4 Aug 2026.